Prelude Therapeutics, Inc. PRLD 深 滬
已收盤 02-06 16:00:00 美东时间
2.17
+0.150
+7.43%
華盛通- 最 高2.21
- 今 開2.07
- 成交量 22.18万股
- 最 低 1.98
- 昨 收 2.02
- 總市值 1.36亿
- 52周最高 4.22
- 市盈率 靜 --
- 換手率 0.35%
- 52周最低 0.6101
- 委 比 85.22%
- 總股本 6286.53万
- 歷史最高 95.375
- 量 比 0.70
- 振 幅 11.39%
- 歷史最低 0.6101
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BUZZ-U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW
BUZZ-U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes rose on Tuesday as Palantir's results aided o
02-04 00:02
Prelude Therapeutics Wins FDA IND Clearance for PRT12396
The latest update is out from Prelude Therapeutics ( ($PRLD) ). On February 3, ...
02-03 22:24
BRIEF-Prelude Therapeutics Receives FDA Clearance Of Investigational New Drug Application (Ind) For Prt12396, A Mutant-Selective Jak2v617f Inhibitor
BRIEF-Prelude Therapeutics Receives FDA Clearance Of Investigational New Drug Application (Ind) For Prt12396, A Mutant-Selective Jak2v617f Inhibitor Feb 3 (Reuters) - Prelude Therapeutics Inc PRLD.O : PRELUDE THERAPEUTICS RECEIVES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR PRT12
02-03 22:04
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Prelude Therapeutics announced FDA clearance to proceed with a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor targeting patients with polycythemia vera and myelofibrosis. The Phase 1 trial, expected to begin dosing in Q2 2026, will assess safety, efficacy, and PK profile in high-risk PV and intermediate/high-risk MF patients. PRT12396, developed under an exclusive option agreement with Incyte, is designed to selectively target...
02-03 14:00
Prelude Therapeutics unveils strategic investor presentation on pipelines
Prelude Therapeutics ( ($PRLD) ) has shared an update. On January 9, 2026, Prel...
01-09 20:59
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Prelude Therapeutics在第67届美国血液学会年会上展示了其针对骨髓增殖性肿瘤（MPN）的两项重要研究进展。首先，其JAK2V617F选择性JH2抑制剂PRT12396在临床前研究中表现出显著的疾病修饰潜力，可选择性抑制突变JAK2活性而不影响正常JAK2功能。PRT12396已完成GLP毒理学研究，计划于2026年第一季度提交IND申请。其次，其靶向突变钙网蛋白（mCALR）的降解剂抗体偶联物（DAC）与CDK9降解剂负载结合，在临床前研究中显示了对恶性细胞的深度选择性杀伤，同时保留健康造血细胞，具有潜在的疾病修饰作用。两项研究均旨在为MPN患者提供创新的疾病修饰疗法。
2025-12-06 16:00
Prelude Therapeutics Q3 EPS $(0.26) Beats $(0.36) Estimate, Sales $6.500M Up From $3.000M YoY
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 28.77 percent. This is a 39.53 percent increase over losses of $(0.43) per share
2025-11-12 20:06
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics reported Q3 2025 financials with $58.2M in cash and a runway into 2027. Key pipeline updates include advancing JAK2V617F inhibitor and KAT6A degrader candidates, with IND filings expected in 2026. The company also presented preclinical data at ASH 2025 and expanded collaborations with Incyte and AbCellera. Research and development expenses decreased to $21.7M, and net loss was $19.7M. An investor conference call is scheduled ...
2025-11-12 12:01
Prelude Therapeutics Signs Option Agreement with Incyte
Prelude Therapeutics ( ($PRLD) ) has provided an update. On November 3, 2025, P...
2025-11-04 22:18
Market-Moving News for November 4th
PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patients With Myeloproliferative Neoplasms NSP: -32% | Insperity shares are trading
2025-11-04 20:24
